News
XCUR
12.83
-2.95%
-0.39
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 1d ago
Weekly Report: what happened at XCUR last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at XCUR last week (0224-0228)?
Weekly Report · 03/03 11:47
Weekly Report: what happened at XCUR last week (0217-0221)?
Weekly Report · 02/24 11:47
Weekly Report: what happened at XCUR last week (0210-0214)?
Weekly Report · 02/17 11:44
Weekly Report: what happened at XCUR last week (0203-0207)?
Weekly Report · 02/10 11:36
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 02/07 12:05
Weekly Report: what happened at XCUR last week (0127-0131)?
Weekly Report · 02/03 11:42
Weekly Report: what happened at XCUR last week (0120-0124)?
Weekly Report · 01/27 11:46
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 01/23 12:05
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes
Barchart · 01/23 06:44
Closing Bell Movers: Electronic Arts down over 10% on guidance cut
TipRanks · 01/22 23:00
Exicure announces purchase agreement with GPCR Therapeutics
TipRanks · 01/22 21:05
Exicure signs purchase agreement with GPCR Therapeutics
Seeking Alpha · 01/22 21:05
*Exicure to Pay Recurring Royalty Payment Based on at Least 10% of Net Sales >XCUR
Dow Jones · 01/22 21:04
Exicure Enters Share Purchase Agreement With GPCR Therapeutics
Benzinga · 01/22 21:03
*Exicure, GPCR Entered Into License and Collaboration Agreement to Further Develop and Commercialize GPCR's Technologies >XCUR
Dow Jones · 01/22 21:03
*Exicure to Make Milestone Payments to GPCR Upon Achievement of Specific Milestones >XCUR
Dow Jones · 01/22 21:03
EXICURE INC: ACQUIRED FROM GPCR ALL OF ISSUED AND OUTSTANDING EQUITY SECURITIES OF GPCR THERAPEUTICS USA INC
Reuters · 01/22 21:01
EXICURE - CO, GPCR ENTER LICENSE AND COLLABORATION AGREEMENT TO FURTHER DEVELOP, COMMERCIALIZE GPCR’S TECHS RELATED TO CERTAIN IP, PATENTS
Reuters · 01/22 21:01
More
Webull provides a variety of real-time XCUR stock news. You can receive the latest news about Exicure Inc through multiple platforms. This information may help you make smarter investment decisions.
About XCUR
More
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.